Dynamic Technology Lab Private Ltd Grows Holdings in Eyepoint Pharmaceuticals, Inc. $EYPT

Key Points

• Dynamic Technology Lab Private Ltd has increased its stake in Eyepoint Pharmaceuticals by 127.8%, acquiring an additional 41,132 shares and bringing its total to 73,310 shares.
• Eyepoint Pharmaceuticals experienced a net loss with an EPS of (0.85), missing analyst expectations, and reported revenue of $5.33 million for the last quarter.
• Analysts have generally rated Eyepoint Pharmaceuticals with a "Buy" rating, with a consensus price target of $26.86, slightly below HC Wainwright's target of $23.00.

Dynamic Technology Lab Private Ltd raised its stake in Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 127.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 73,310 shares of the company's stock after purchasing an additional 41,132 shares during the period. Dynamic Technology Lab Private Ltd owned 0.11% of Eyepoint Pharmaceuticals worth $397,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in Eyepoint Pharmaceuticals in the fourth quarter valued at $76,000. GAMMA Investing LLC increased its stake in Eyepoint Pharmaceuticals by 3,174.4% in the first quarter. GAMMA Investing LLC now owns 10,249 shares of the company's stock valued at $56,000 after purchasing an additional 9,936 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new stake in Eyepoint Pharmaceuticals in the fourth quarter valued at $91,000. Arizona State Retirement System increased its stake in Eyepoint Pharmaceuticals by 12.7% in the first quarter. Arizona State Retirement System now owns 16,600 shares of the company's stock valued at $90,000 after purchasing an additional 1,877 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in Eyepoint Pharmaceuticals by 208.8% in the first quarter. New York State Common Retirement Fund now owns 20,114 shares of the company's stock valued at $109,000 after purchasing an additional 13,600 shares in the last quarter. 99.41% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Chardan Capital reaffirmed a "buy" rating and issued a $27.00 price target on shares of Eyepoint Pharmaceuticals in a research note on Thursday, August 7th. Royal Bank Of Canada started coverage on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, June 17th. They set an "outperform" rating and a $28.00 target price for the company. Finally, HC Wainwright boosted their target price on shares of Eyepoint Pharmaceuticals from $22.00 to $23.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $26.86.

Eyepoint Pharmaceuticals Price Performance

Shares of NASDAQ:EYPT traded up $0.39 during midday trading on Wednesday, hitting $13.99. 230,166 shares of the company's stock were exchanged, compared to its average volume of 801,091. Eyepoint Pharmaceuticals, Inc. has a 12 month low of $3.91 and a 12 month high of $14.42. The company has a market cap of $963.99 million, a PE ratio of -5.21 and a beta of 1.93. The stock has a 50 day moving average price of $11.26 and a 200-day moving average price of $8.42.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.18). Eyepoint Pharmaceuticals had a negative return on equity of 63.80% and a negative net margin of 337.93%.The firm had revenue of $5.33 million for the quarter, compared to analysts' expectations of $6.82 million. On average, analysts anticipate that Eyepoint Pharmaceuticals, Inc. will post -2.13 EPS for the current fiscal year.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.